HEERLEN, Netherlands, March 26, 2019 /PRNewswire/ --
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, announces that at the Annual General Meeting of Shareholders to be held on 8 May 2019, the DSM Supervisory Board will nominate for appointment as a new Supervisory Board member: Mrs. Erica Mann. The Supervisory Board will also nominate Mrs. Pauline van der Meer Mohr for re-appointment to the Supervisory Board.
(Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )
The aim of these nominations is to maintain and further strengthen the Supervisory Board's profile in terms of international business experience and experience in executive leadership of large corporations. Mrs. Mann will extend the Supervisory Board's knowledge and competence base with respect to (infant) nutrition, Fast-Moving Consumer Goods and pharma in science-based businesses. With Mrs. Van der Meer Mohr's re-appointment, the Board will maintain its strong profile in the areas of human resources management and corporate governance.
Mrs. Mann (1958, Australian national) was a member of the Board of Management of the Bayer Group and Global President of Bayer's Consumer Health Division until early 2018. Before that Mrs. Mann was with Pfizer Inc. (2009-2011) and with Wyeth Group (1994-2009) where she held senior executive positions. Mrs. Mann is a non-executive member of the Board of Soho Flordis since August 2018 and of the Board of Kellogg company since February 2019. She has also been nominated to join the Board of Perrigo as a non-executive director.
In 2011, Mrs. Pauline van der Meer Mohr (1960, Dutch national) was first appointed to the DSM Supervisory Board. It is proposed to re-appoint her as a member of the Supervisory Board of DSM for a period of two years. Her last executive position held was President of the Executive Board of Erasmus University Rotterdam. Mrs. Van der Meer Mohr holds several non-executive and advisory roles, including those of non-executive director in the boards of HBSC Holdings plc. and Mylan N.V., Chair of the Supervisory Board of EY Netherlands, member of the selection and nomination committee of the Dutch Supreme Court and Chair of the Dutch Corporate Governance Code Monitoring Committee.
Upon appointment by the AGM of these nominated candidates, DSM's Supervisory Board's composition will be even more diverse in terms of gender, nationality, background, knowledge and experience. The Supervisory Board will then consist of eight members, including five different nationalities and four female members (50%).
More information on the proposed appointment and re-appointment can be found in the Notes to the Agenda for the Annual General Meeting of Koninklijke DSM N.V. to be held on Wednesday 8 May 2019, published today.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about EUR10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
For more information:
DSM Media Relations Lieke de Jong tel. +31(0)45-5782420 e-mail email@example.com
DSM Investor Relations Dave Huizing tel. +31(0)45-5782864 e-mail firstname.lastname@example.org